- Scopus BioPharma Inc (NASDAQ:SCPS) has acquired Los Angeles-based Olimmune Inc for an undisclosed amount.
- Olimmune is a developer of oligonucleotide immunotherapies for treatment-resistant and metastatic cancers.
- Olimmune’s lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. INDs for these indications will be submitted by Q1 of 2023.
- Olimmune has exclusive, worldwide licenses to certain patents from the City of Hope to develop and commercialize CpG-STAT3ASO and CpG-STAT3decoy.
- Price Action: SCPS shares are down 1.12% to $7.05 during the market session on the last check Wednesday.
Excelerate Energy Q2 EPS $(0.08) May Not Compare To $0.11 Estimate, Sales $622.90M Beat $591.67M Estimate
Excelerate Energy (NYSE:EE) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.11 by 172.73 percent. The company reported quarterly sales of $622.90 million which beat the
